Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 4, 2006, Pages 475-482

  Turner, P Kellie ^a   Iacono, Lisa C ^a   Panetta, John C ^a,b   Santana, Victor M ^a,b   Daw, Najat C ^a,b   Gajjar, Amar ^a,b   Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Limited sampling model; Pharmacokinetics; Topotecan

Indexed keywords

TOPOTECAN; TOPOTECAN LACTONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; HUMAN; INFANT; LIMITED SAMPLING MODEL; MAJOR CLINICAL STUDY; MODEL; MONTE CARLO METHOD; NEWBORN; PEDIATRICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; TIME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; INJECTIONS, INTRAVENOUS; MODELS, STATISTICAL; MONTE CARLO METHOD; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TOPOTECAN;

EID: 30644471976     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0062-z     Document Type: Article

References (28)

1. Beal SL, Sheiner LB (1992) NONMEM users' guide
2. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739
3. D'Argenio DZ, Schumitzky A (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software
4. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF (2004) Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 22:829
5. Del Bino G, Lassota P, Darzynkiewicz Z (1991) The S-phase cytotoxicity of camptothecin. Exp Cell Res 193:27
6. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C (2002) Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol 20:1617
7. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
8. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393
9. Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Danks MK, Houghton JA (1996) Schedule dependent efficacy of camptothecins in models of human cancer. NY Acad Sci 803:188
10. Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229
11. Leger F, Loos WJ, Fourcade J, Bugat R, Goffinet M, Mathijssen RH, Verweij J, Sparreboom A, Chatelut E (2004) Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 90:343
12. Mahmood I (2000) Limited sampling model for the estimation of pharmacokinetic parameters in children. Ther Drug Monit 22:532
13. Minami H, Beijnen JH, Verweij J, Ratain MJ (1996) Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res 2:43
14. Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Deporte-Fety R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E (2000) Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 46:375
15. Panetta JC, Iacono LC, Adamson PC, Stewart CF (2003) The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res 9:5068
16. Reed MD (1999) Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics 104:627
17. Santana VM, Furman WL, Billups CA, Koffer F, Davidoff AM, Houghton PJ, Stewart CF (2005) Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol
18. Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajijar A, Houghton PJ, Stewart CF (2003) A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633
19. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503
20. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB (1994) Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946
21. Stewart CF, Liu CY, Zamboni WC, Ma MK, Kirstein MN, Hanna SK, Gajjar AJ, Santana VM, Houghton PJ, Sambol NC (2000) Population pharmacokinetics of topotecan in children and adolescents. Proc Am Soc Clin Oncol 19:177a
22. Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A (2004) Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 22:3357
23. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ (1996) Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Ped Hem/Onc 18:352
24. van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, Maes RA, Beijnen JH (1995) Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 35:237
25. van Warmerdam LJ, Verweij J, Rosing H, Schellens JH, Maes RA, Beijnen JH (1994) Limited sampling models for topotecan pharmacokinetics. Ann Oncol 5:259
26. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Xiaolong Luo, Poquette C, Houghton JA, Houghton PJ (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505
27. Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF (1999) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 43:454
28. Zamboni WC, Crom WR, Bowman LC, Pratt CB, Houghton PJ, Stewart CF (1996) Interpatient variability in oral (PO) absorption of topotecan (TPT) in children with relapsed solid tumors. Clinical Pharmacology Ther 59:198